For Biotech Dealmakers, It’s Everything, Everywhere All at Once

Biotech executives are reaching into a deep bag of tricks to come up with the best possible ways to live up to their ultimate potential. The dual-track option, where a company pursues both an IPO and an acquisition, is becoming not just the norm, but a necessity. Some are taking it a step further, many industry experts told Fierce Biotech on the sidelines of the J.P. Morgan Healthcare Conference last week. “There are three tracks. We have clients that are pursuing IPO funding, or licensing or M&A. And it’s really which will come together first,” said Randy Sunberg, chair of the North America Healthcare & Life Sciences Group, and partner in the transactions group for Baker & Mckenzie.

Read the full article: For Biotech Dealmakers, It’s Everything, Everywhere All at Once //

Source: https://www.fiercebiotech.com/biotech/biotech-dealmakers-its-everything-everywhere-all-once

Leave a Comment

Your email address will not be published.

Scroll to Top